Stryker Asia Pacific — Net Sales remained flat by 0.0% to $505.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 3.8%, from $486.50M to $505.00M. Over 3 years (FY 2021 to FY 2024), Asia Pacific — Net Sales shows relatively stable performance with a 0.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market share or higher demand for the company's medical products in the region, while a decrease may signal competitive pressure or economic headwinds.
This metric represents the total revenue generated from the sale of medical devices, equipment, and services within the...
Comparable to regional revenue reporting by other multinational medical device manufacturers, often benchmarked against regional GDP growth and healthcare spending trends.
syk_segment_asia_pacific_net_sales| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $1.97B | $1.89B | $1.95B | $2.02B |
| YoY Change | — | -4.5% | +3.2% | +3.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.